Innate Pharma S.A.

IPHYF · OTC
Analyze with AI
6/30/2025
12/31/2024
6/30/2024
12/31/2023
Operating Activities
Net Income-$21,344-$24,707-$24,764-$7,570
Dep. & Amort.$707$852$1,142$723
Deferred Tax$0$0$0$0
Stock-Based Comp.$1,554$2,238$1,706$2,855
Change in WC-$9,959$7,852$31,310-$6,524
Other Non-Cash-$2,122$3,833-$7,876-$32
Operating Cash Flow-$31,164-$9,932$3,036-$21,093
Investing Activities
PP&E Inv.-$58-$108-$283-$21
Net Acquisitions$0$0$0$300
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$9,590$0$0
Other Inv. Act.$7,032-$1,214$749$10,159
Investing Cash Flow$6,974$8,268$466$10,438
Financing Activities
Debt Repay.-$4,456-$8,936$0$0
Stock Issued$0$0$0$94
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$14,932$8,096-$2,164-$720
Financing Cash Flow$10,476-$841-$2,164-$720
Forex Effect$1,022-$124-$129$129
Net Chg. in Cash$53,704$66,704-$308-$809
Supplemental Information
Beg. Cash$0-$308$0$71,414
End Cash$53,704$66,396-$308$70,605
Free Cash Flow-$31,222-$10,040$2,753-$21,135